From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life

Schröder, 2009, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 1320, 10.1056/NEJMoa0810084 de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ, ERSPC Rotterdam Study Group. A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.016. Schröder, 2012, Prostate-cancer mortality at 11 years of follow-up, N Engl J Med, 366, 981, 10.1056/NEJMoa1113135 Getaneh, 2020, Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: a micro-simulation study of 230 scenarios, Cancer Med, 9, 7742, 10.1002/cam4.3395 Heijnsdijk, 2012, Quality-of-life effects of prostate-specific antigen screening, N Engl J Med, 367, 595, 10.1056/NEJMoa1201637 Roobol, 2013, Screening for prostate cancer: results of the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer, Eur Urol, 64, 530, 10.1016/j.eururo.2013.05.030 Van Poppel, 2021, Early detection of prostate cancer in 2020 and beyond: facts and recommendations for the European Union and the European Commission, Eur Urol, 79, 327, 10.1016/j.eururo.2020.12.010 Hugosson, 2019, A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer, Eur Urol, 76, 43, 10.1016/j.eururo.2019.02.009 Jemal, 2021, Prostate cancer incidence 5 years after US Preventive Services Task Force recommendations against screening, J Natl Cancer Inst, 113, 64, 10.1093/jnci/djaa068 D'Amico, 2003, Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era, J Clin Oncol, 21, 2163, 10.1200/JCO.2003.01.075 Yossepowitch, 2008, Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy, Eur Urol, 53, 950, 10.1016/j.eururo.2007.10.008 Adam, 2017, Functional outcomes and quality of life after radical prostatectomy only versus a combination of prostatectomy with radiation and hormonal therapy, Eur Urol, 71, 330, 10.1016/j.eururo.2016.11.015 Nguyen, 2015, Adverse effects of androgen deprivation therapy and strategies to mitigate them, Eur Urol, 67, 825, 10.1016/j.eururo.2014.07.010 Bergius, 2020, Health-related quality of life and survival in prostate cancer patients in a real-world setting, Urol Int, 104, 939, 10.1159/000510319 Venderbos, 2021, Europa Uomo Patient Reported Outcome Study (EUPROMS): descriptive statistics of a prostate cancer survey from patients for patients, Eur Urol Focus, 7, 987, 10.1016/j.euf.2020.11.002 Green, 2002, Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial, BJU Int, 90, 427, 10.1046/j.1464-410X.2002.02917.x Melloni, 2020, Effect of androgen deprivation therapy on metabolic complications and cardiovascular risk, J Cardiovasc Transl Res, 13, 451, 10.1007/s12265-019-09942-w Sari Motlagh, 2021, The risk of new onset dementia and/or Alzheimer disease among patients with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis, J Urol, 205, 60, 10.1097/JU.0000000000001341 Donovan, 2016, Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer, N Engl J Med, 375, 1425, 10.1056/NEJMoa1606221 McIntosh, 2022, Why do men with prostate cancer discontinue active surveillance for definitive treatment? A mixed methods investigation, Psychooncology, 31, 1420, 10.1002/pon.5947 Bokhorst, 2016, Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study, BJU Int, 118, 366, 10.1111/bju.13410 Van Hemelrijck, 2019, Reasons for discontinuing active surveillance: assessment of 21 centres in 12 countries in the Movember GAP3 Consortium, Eur Urol, 75, 523, 10.1016/j.eururo.2018.10.025 Marzouk, 2018, Long-term cancer specific anxiety in men undergoing active surveillance of prostate cancer: findings from a large prospective cohort, J Urol, 200, 1250, 10.1016/j.juro.2018.06.013 van den Bergh, 2007, Prospective validation of active surveillance in prostate cancer: the PRIAS study, Eur Urol, 52, 1560, 10.1016/j.eururo.2007.05.011 Boevee, 2010, Change of tumour characteristics and treatment over time in both arms of the European Randomized Study of Screening for Prostate Cancer, Eur J Cancer, 46, 3082, 10.1016/j.ejca.2010.09.033 Bechis, 2011, Impact of age at diagnosis on prostate cancer treatment and survival, J Clin Oncol, 29, 235, 10.1200/JCO.2010.30.2075 Kregting, 2022, Finding the optimal mammography screening strategy: a cost-effectiveness analysis of 920 modelled strategies, Int J Cancer, 151, 287, 10.1002/ijc.34000 Remmers, 2019, Predicting biochemical recurrence and prostate cancer-specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of patients with screening- and clinically detected prostate cancer, BJU Int, 124, 635, 10.1111/bju.14790 Drost, 2019, Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer, Cochrane Database Syst Rev, 4 Eklund, 2021, MRI-targeted or standard biopsy in prostate cancer screening, N Engl J Med, 385, 908, 10.1056/NEJMoa2100852 Mannaerts, 2018, Prostate cancer risk assessment in biopsy-naive patients: the Rotterdam Prostate Cancer Risk Calculator in multiparametric magnetic resonance imaging-transrectal ultrasound (TRUS) fusion biopsy and systematic TRUS biopsy, Eur Urol Oncol, 1, 109, 10.1016/j.euo.2018.02.010 van der Leest, 2019, Eur Urol, 75, 570, 10.1016/j.eururo.2018.11.023 Tomer, 2021, Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance, BJU Int, 127, 96, 10.1111/bju.15136 Fossa, 2019, Improved patient-reported functional outcomes after nerve-sparing radical prostatectomy by using NeuroSAFE technique, Scand J Urol, 53, 385, 10.1080/21681805.2019.1693625 Avulova, 2018, The effect of nerve sparing status on sexual and urinary function: 3-year results from the CEASAR study, J Urol, 199, 1202, 10.1016/j.juro.2017.12.037 Spratt, 2017, Vessel-sparing radiotherapy for localized prostate cancer to preserve erectile function: a single-arm phase 2 trial, Eur Urol, 72, 617, 10.1016/j.eururo.2017.02.007 Wolters, 2010, The effect of study arm on prostate cancer treatment in the large screening trial ERSPC, Int J Cancer, 126, 2387, 10.1002/ijc.24870 Bokhorst, 2015, Do treatment differences between arms affect the main outcome of ERSPC Rotterdam?, J Urol, 194, 336, 10.1016/j.juro.2015.02.045 Carlsson, 2019, Could differences in treatment between trial arms explain the reduction in prostate cancer mortality in the European Randomized Study of Screening for Prostate Cancer?, Eur Urol, 75, 1015, 10.1016/j.eururo.2019.03.010